Hypertension in pregnancy: diagnosis and management

50 mg to 150 mg daily), and that common practice in the UK was to offer 75 mg to 150 mg, therefore this dose range was recommended. The committee were aware of the link between chronic hypertension and both pre-existing and gestational diabetes, therefore they made an overarching recommendation at the beginning of the guideline to cross-refer to the existing NICE guideline on diabetes in pregnancy. The committee made a new recommendation referring to the NICE diagnostics guidance on placental growth factor (PLGF) testing as this may be applicable to women with chronic hypertension. As there is currently a lack of evidence on the difference in outcomes between different antihypertensive medications, and concerns about possible adverse neonatal events from beta blockers, the committee made research recommendations on these topics. How the recommendations might affect practice Based on these recommendations, a clear blood pressure target should now be set for women with chronic hypertension in pregnancy who need antihypertensive treatment to improve consistency of treatment targets. Starting treatment for hypertension and offering aspirin to women with chronic hypertension who are pregnant are standard care, so these recommendations are not expected to change practice significantly. Return to recommendations Monitoring and treatment of
